Fragment‐Based Design of Targeted Covalent Inhibitors: The Scope and Limitation of Linking Approaches
ChemMedChem · 2026
DOI: 10.1002/cmdc.202501108 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2026. Verfasst von Levente Kollár und 8 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal Chemistry Research Group and Drug Innovation Centre, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary. Hauptthemen laut MEDLINE: Drug Design, SARS-CoV-2, Coronavirus 3C Proteases, Protease Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nemzeti Kutatási Fejlesztési és Innovációs Hivatal, Hungarian Academy of Sciences, Slovenian Research and Innovation Agency - ARIS.
Abstract (Originalsprache)
Linking of fragments in neighboring binding sites is one of the optimization strategies in fragment‐based drug discovery, where additive or even more substantial bioactivity improvements can be realized. However, such efforts present a considerable challenge when one fragment binds covalently to the target protein, as small modifications can influence the correct positioning of the covalent warhead toward the targeted nucleophilic residue. Here, we present a case study of fragment linking that yielded single‐digit micromolar, covalent inhibitors of the SARS‐CoV‐2 main protease, starting from fragments that were inactive in the biochemical assay. Using structural information from a recent, high‐throughput crystallographic fragment screen, we show that the success of fragment linking in the design of targeted covalent inhibitors is heavily impacted by several factors, including the warhead type, the labeling chemistry, and even subtle changes in the designed linker. Notably, we observe that induced fit effects might override the original fragment orientations in the linked molecule, highlighting the need for reliable structure verification, especially in consecutive rounds of fragment elaboration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medicinal Chemistry Research Group and Drug Innovation Centre, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary.
- Department of Organic Chemistry and Technology, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, Budapest, Hungary.
- Department of Medicinal Chemistry, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
- MS Metabolomics Research Group, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary.
- Diamond Light Source, Harwell Science and Innovation Campus, Didcot, UK.
- Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot, UK.
ORCID-Profile: Levente Kollár, Levente M Mihalovits, Dávid Bajusz, Damijan Knez, József Simon, Blake H Balcomb, Daren Fearon, Stanislav Gobec, György M Keserű
Förderung
- Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
- Hungarian Academy of Sciences
- Slovenian Research and Innovation Agency - ARIS
Zitieren
APA
Kollár, L., Mihalovits, L. M., Bajusz, D., Knez, D., Simon, J., Balcomb, B. H., Fearon, D., Gobec, S., & Keserű, G. M. (2026). Fragment‐Based Design of Targeted Covalent Inhibitors: The Scope and Limitation of Linking Approaches. ChemMedChem. https://doi.org/10.1002/cmdc.202501108
Vancouver
Kollár L, Mihalovits LM, Bajusz D, Knez D, Simon J, Balcomb BH, et al. Fragment‐Based Design of Targeted Covalent Inhibitors: The Scope and Limitation of Linking Approaches. ChemMedChem. 2026. doi:10.1002/cmdc.202501108
BibTeX
@article{Kollr2026,
author = {Kollár, Levente and Mihalovits, Levente M and Bajusz, Dávid and Knez, Damijan and Simon, József and Balcomb, Blake H and Fearon, Daren and Gobec, Stanislav and Keserű, György M},
title = {Fragment‐Based Design of Targeted Covalent Inhibitors: The Scope and Limitation of Linking Approaches},
journal = {ChemMedChem},
year = {2026},
doi = {10.1002/cmdc.202501108}
}
EUVIMED